Clinical Trials Logo

Clinical Trial Summary

This research work is important for the cure/control of HIV infection. The objectives of a treatment case on HIV patient is essentially to bring down the viral load closer to undetectable level. The studies are depend on the potential influence of 'Kallunk Oxide' on the CD4+ T cells and the effectiveness on surface of HIV-1. The basic study is to break surface protein and directly inhibit a protein's increased functions, not only in the CD4+T cell but also CD3 and CD8+ T cells, by appropriate antidote.

The 'Yogaprabhava', the drug's effectiveness, and progressive immunity with diet and lifestyle can be more easily studied.


Clinical Trial Description

This research was individual investigator initiated meritorious project to identify potential roles for the safe and effective use of Complementary and Alternative Medicine CAM in the treatment of HIV infection.

This modest Phase-I and phase II clinical trials were intervention Studies. In the case of HIV infections, these studies were formulated each 20 random numbered batch. The Principal Investigator (PI) selects the informed consented patients and the recruited study was adhered by Helsinki Declaration.

Selection of subjects: HIV patients with CD3, CD4, and CD8 + T cell counts >450 cu/mm^3 were enrolled in Wing No: 1 group. HIV patients with CD+ T cell counts >450 cu/mm^3 were recruited for basic Arm study. The selected Arm - 1 of this research, the specific and potential milestone on baseline CD+T cell counts >450 cu/mm^3 was determined from the outcomes of previously conducted Observational Phase-1 study data.

The statistical evaluation laboratory on parameters in exists group was measured through Immune Cells Count Assay. The prolonged viral suppression and reversal of HIV seropositivity were the ultimate research outcomes and this study was evaluated the safety and efficacy of this drug. Absolute assays of Viral Load, Lymphocyte Enumeration, Western Blot blood test and convinced mean values and reference range methods were adopted for laboratory study.

The drug was administered as optimal doses 200 mg and 500 mg to study subjects, respectively, between 8 and 17 years old children and 18 and 65 years old Men and Women as anticipated 500 Female and 500 Male participants. The ELISA/P-24 test was used to confirm HIV-seropositivity.

The patients safe and effective optimum dose was the primary out come measure and the Viral Load assay and Immune Cells Count assay were the secondary outcome measure.

The randomized numbers were arranged with single patient's clinical records. Patient's body weight, CD4 T cells count, skin thickness, body measurements, blood pressure, temperature, pulse rates, anti body count, and other hematological examinations were investigated before and after the treatment period.

The well-designed research team minds the symptoms such as nausea, fatigue,weight loss, sweating, shortness of breath, joint pain etc and the Side effects of this treatment, if any, could be carefully noted. On entry and at the end of this study, the biochemical investigations such as urine examination, serum lipoprotein and cholesterol were individually noted.

Patient's temperature, digestion complaints, or chill, etc could treated by medicine and restricted diets without using mutton soup, milk, and cow ghee. The study was reduced patient's stress as well as depression and also managed the productivity, emotional well being, immunity and quality of life by the practice of this treatment.

The study was handled a transparent privacy environment to recruit HIV-infected people in India.

Dosage:

HIV patients were administered with once daily dose of sample size product, 500 mg for adults and 200 mg for children (up to 8 years old), as one course.

Controlled Nourished diet:

All patients were adhered with nourished diet protocol. The controlled diets were milk (only 1/2 cup), rice and wheat food products, cow ghee, green gram, mutton soup, and prepared black pepper added vegetable foods.

Restriction:

HIV-Patients were not used salts, other oils, mustard, and tamarind fish items within 10 days of this medication use.

Drug Administration:

HIV- patients were used one drug "Kallunk oxide (Immunotherapy)" as calcined/or oxidized molecules. The powder form sample size medicine was put into 1/2 cup hotter water (an adjuvant).

Precaution:

No precautions be needed. Patients were not used sediments at the bottom of the cup. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00276991
Study type Interventional
Source Traditional Alternative Medicine Research, India
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date November 2007
Completion date October 2009

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2